Fully biologically active when compared to standard. The ED 50 as determined by its ability to inhibit APRIL-mediated proliferation of anti-IgM stimulated murine B cells is no less than 40.0 ng/ml, corresponding to a specific activity of > 2.5 × 10 4 IU/mg in the presence of 100.0 ng/ml human APRIL.

BCMA/TNFRSF17 Protein, Human, Recombinant is expressed in E. coli. The accession number is Q02223.

Human

E. coli

Tumor necrosis factor receptor superfamily member 17,TNFRSF17,CD_antigen: CD269,BCM,B-cell maturation protein

Ala5-Ala54

> 98% as determined by SDS-PAGE; > 98% as determined by HPLC

It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml.

Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles.

BCMA, a member of the TNF receptor superfamily, binds to BAFF and APRIL. BCMA is expressed on mature B-cells and other B-cell lines and plays an important role in B cell development, function and regulation. BCMA also has the capability to activate NF-kappaB and JNK. The human BCMA gene codes for a 184 amino acid type I transmembrane protein, which contains a 54 amino acid extracellular domain, a 23 amino acid transmembrane domain, and a 107 amino acid extracellular domain.